Art. -Nr.: HY-175023A

OncoACP3 TFA

Name: OncoACP3 TFA
Brand: MedChemExpress
SKU: HY-175023A
Price: 680.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Kundenbewertung

Based on 1 Customer Validation

OncoACP3 TFA is a small-molecule ligand of prostatic acid phosphatase (ACP3) with an IC₅₀ of 0.30 nM. OncoACP3 TFA has a modular structure that supports flexible payload delivery. After radiolabeling with Lu-177 it selectively accumulates in ACP3-expressing tumors with a long retention time, enabling targeted radiation delivery. OncoACP3 TFA is applicable to research related to prostate cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.87%
Formel: C₆₂H₈₂F₃N₁₂O₁₅P
Molecular Weight:1323.35

Speicherung:

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

OncoACP3 TFA Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

OncoACP3 TFA binds to human recombinant ACP3 with ultra-high affinity, with a dissociation rate of 1.2 × 10^-4 s^-1^[1].
¹⁷⁷Lu-OncoACP3 TFA specifically binds to HT1080.hACP3 and PC3.hACP3 cells expressing ACP3, but does not bind to ACP3-negative wild-type cells^[1].
¹⁷⁷Lu-OncoACP3 TFA specifically localizes to the membranes of HT1080.hACP3 and PC3.hACP3 cells that express ACP3, but does not bind to wild-type cells without ACP3 expression^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .

In Vivo

¹⁷⁷Lu-OncoACP3 (250-1000 MBq/kg, i.v., single administration) TFA induces potent antitumor activity and even complete cure in tumor-bearing mice^[1].
OncoACP3 TFA is conjugated to the cytotoxic agent MMAE (HY-15162) via a cleavable linker to construct the small-molecule drug conjugate OncoACP3 TFA-GlyPro-MMAE, which enables targeted chemotherapy in mouse models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Athymic BALB/c AnNRj-Foxn1 nude mice (male, 4-10 weeks old, subcutaneous flank implantation of HT1080.hACP3 cells)^[1]
Dosage:

5 MBq per injection (250 MBq/kg); 20 MBq per injection (1,000 MBq/kg)
Administration:

i.v.; single injection
Result:

Induced tumor regression in all treated animals at 5 MBq per injection, with 25% (1/4) complete tumor response by therapy day 31.
Achieved 100% (4/4) complete tumor response at 20 MBq per injection.
Showed good tolerability with no excessive body weight loss observed.

Animal Model:

Athymic BALB/c AnNRj-Foxn1 nude mice (female, 4-10 weeks old, subcutaneous flank implantation of HT1080.hACP3 cells)^[1]
Dosage:

62.5 nmol/kg; 125 nmol/kg; 250 nmol/kg; 500 nmol/kg; 1,000 nmol/kg
Administration:

i.v.; single injection
Result:

Reached ~70% of the injected dose per gram (%ID/g) tumor accumulation at 2 hours post-administration at 62.5 nmol/kg, with low kidney uptake of ~3% ID/g.
Maintained high tumor-to-normal organ ratios across all doses.
Showed partial tumor saturation between 250 nmol/kg and 1,000 nmol/kg.

Animal Model:

Athymic BALB/c AnNRj-Foxn1 nude mice (female and male, 4-10 weeks old, subcutaneous flank implantation of HT1080.hACP3 or PC3.hACP3 cells)^[1]
Dosage:

62.5 nmol/kg
Administration:

i.v.; single injection
Result:

Exhibited a tumor half-life of ~72 hours in female mice with HT1080.hACP3 tumors.
Showed a tumor half-life exceeding 72 hours in male mice with PC3.hACP3 tumors.
Demonstrated low accumulation in all healthy organs, including salivary glands and reproductive tissues, across all time points.

Animal Model:

Athymic BALB/c AnNRj-Foxn1 nude mice (subcutaneous flank implantation of HT1080.hACP3 or PC3.hACP3 cells)^[1]
Dosage:

250 nmol/kg
Administration:

i.v.; repeated injections as scheduled
Result:

Delivered ~150 pmol/g of MMAE to HT1080.hACP3 tumors and ~15 pmol/g of MMAE to PC3.hACP3 tumors at 24 hours post-administration, with minimal MMAE accumulation in healthy organs.
Significantly inhibited tumor growth in both HT1080.hACP3 and PC3.hACP3 tumor models compared to vehicle or non-cleavable OncoACP3-MMAE, with greater efficacy observed in the HT1080.hACP3 model.

Chemical Information

Appearance Solid
Molecular Weight 1323.35
Formel C₆₂H₈₂F₃N₁₂O₁₅P
Color White to off-white
SMILES

OC(CN1CCN(CC(NCCCCCCNC([C@H]2N(C(CN(CC3=CC=CC=C3)CC4=CC=CC=C4)=O)C[C@@H](N5N=NC(COC6=CC=C(C(NCC7=CC=CC=C7)P(O)(O)=O)C=C6)=C5)C2)=O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)=O.OC(C(F)(F)F)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (75.57 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.7557 mL

3.7783 mL

7.5566 mL

5 mM

0.1511 mL

0.7557 mL

1.5113 mL

10 mM

0.0756 mL

0.3778 mL

0.7557 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (1.89 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (1.89 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (1.89 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Georgiev T, et al. Discovery of high-affinity ligands for prostatic acid phosphatase via DNA-encoded library screening enables targeted cancer therapy. Nat Biomed Eng. 2026;10(1):178-191. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.7557 mL	3.7783 mL	7.5566 mL	18.8915 mL
	5 mM	0.1511 mL	0.7557 mL	1.5113 mL	3.7783 mL
	10 mM	0.0756 mL	0.3778 mL	0.7557 mL	1.8891 mL
	15 mM	0.0504 mL	0.2519 mL	0.5038 mL	1.2594 mL
	20 mM	0.0378 mL	0.1889 mL	0.3778 mL	0.9446 mL
	25 mM	0.0302 mL	0.1511 mL	0.3023 mL	0.7557 mL
	30 mM	0.0252 mL	0.1259 mL	0.2519 mL	0.6297 mL
	40 mM	0.0189 mL	0.0945 mL	0.1889 mL	0.4723 mL
	50 mM	0.0151 mL	0.0756 mL	0.1511 mL	0.3778 mL
	60 mM	0.0126 mL	0.0630 mL	0.1259 mL	0.3149 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

OncoACP3 TFA